AOLS (Aeolus Pharmaceuticals) Cyclically Adjusted PS Ratio: (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aeolus Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Aeolus Pharmaceuticals  (OTCPK:AOLS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Aeolus Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms


Aeolus Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Aeolus Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aeolus Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Aeolus Pharmaceuticals Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Aeolus Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AOLS vs RDGL, PCYN, YBAO: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aeolus Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aeolus Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aeolus Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Aeolus Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Aeolus Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Aeolus Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2017 is calculated as:

For example, Aeolus Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2017 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2017 (Change)*Current CPI (Jun. 2017)
=0/244.9550*244.9550
=0.000

Current CPI (Jun. 2017) = 244.9550.

Aeolus Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200709 0.000 208.490 0.000
200712 0.000 210.036 0.000
200803 0.000 213.528 0.000
200806 0.000 218.815 0.000
200809 0.000 218.783 0.000
200812 0.000 210.228 0.000
200903 0.000 212.709 0.000
200906 0.000 215.693 0.000
200909 0.000 215.969 0.000
200912 0.000 215.949 0.000
201003 0.000 217.631 0.000
201006 0.000 217.965 0.000
201009 0.000 218.439 0.000
201012 0.000 219.179 0.000
201103 0.006 223.467 0.007
201106 0.022 225.722 0.024
201109 0.024 226.889 0.026
201112 0.028 225.672 0.030
201203 0.031 229.392 0.033
201206 0.023 229.478 0.025
201209 0.020 231.407 0.021
201212 0.020 229.601 0.021
201303 0.009 232.773 0.009
201306 0.006 233.504 0.006
201309 0.007 234.149 0.007
201312 0.006 233.049 0.006
201403 0.011 236.293 0.011
201406 0.036 238.343 0.037
201409 0.018 238.031 0.019
201412 0.007 234.812 0.007
201503 0.009 236.119 0.009
201506 0.000 238.638 0.000
201509 0.007 237.945 0.007
201512 0.002 236.525 0.002
201603 0.004 238.132 0.004
201606 0.004 241.018 0.004
201609 0.004 241.428 0.004
201612 0.001 241.432 0.001
201703 0.001 243.801 0.001
201706 0.000 244.955 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aeolus Pharmaceuticals Business Description

Address 26361 Crown Valley Parkway, Suite 150, Mission Viejo, CA, USA, 92691
Aeolus Pharmaceuticals Inc is a Southern California-based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.